Targeted cancer therapy: The future of drug combinations

Meira, Débora Dummer; Casotti, Matheus Correia; Braga, Raquel Furlani Rocon; Filho, Luiz C.G.S.; Guimarães, Alessandra P.; Campanharo, Camilly V.; Duque, Daniel A.; Barbosa, Débora G.; Lopes, Lorena M.; Kohls, Victor N.G.; Alves, Lyvia Neves Rebello; García, Francisco Debesa; Vieira, Fernando L.H.; Almeida, Vitor; Santos, Eldamaria V.W.; Reis, Raquel S.; Louro, Iúri Drumond

doi:10.1016/b978-0-12-821584-5.00032-8

Cited by 3 publications

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HER2 (human epidermal growth factor receptor 2), encoded by the ERBB2 gene, is a member of the human epidermal growth factor receptor family, along with HER1, HER3, and HER4 [3,51]. In BC, ERBB2 amplification and consequent overexpression occurs in 13-15% of cases and is related to a worse prognosis due to the high metastatic potential of HER2-positive tumors [3,31,52].…”

Section: Her2mentioning

confidence: 99%

Biomarkers in Breast Cancer: An Old Story with a New End

Alves

Meira

Merigueti

et al. 2023

Genes

View full text Add to dashboard Cite

Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease and the leading cause of cancer mortality in women. Advances in molecular technologies allowed for the identification of new and more specifics biomarkers for breast cancer diagnosis, prognosis, and risk prediction, enabling personalized treatments, improving therapy, and preventing overtreatment, undertreatment, and incorrect treatment. Several breast cancer biomarkers have been identified and, along with traditional biomarkers, they can assist physicians throughout treatment plan and increase therapy success. Despite the need of more data to improve specificity and determine the real clinical utility of some biomarkers, others are already established and can be used as a guide to make treatment decisions. In this review, we summarize the available traditional, novel, and potential biomarkers while also including gene expression profiles, breast cancer single-cell and polyploid giant cancer cells. We hope to help physicians understand tumor specific characteristics and support decision-making in patient-personalized clinical management, consequently improving treatment outcome.

show abstract

Section: Her2mentioning

confidence: 99%

Biomarkers in Breast Cancer: An Old Story with a New End

Alves

Meira

Merigueti

et al. 2023

Genes

View full text Add to dashboard Cite

show abstract

“…Resistance to target therapy can be developed by two mechanisms: (1) primary resistance or (2) acquired resistance, also known as on-target and off-target, respectively [4,92]. The first is related to mutations in the drug's primary molecular target, leading to low or no response, while off-target resistance is related to responses in parallel signaling pathways or downstream of the target [4,92].…”

Section: Resistance To Mabs and Tkismentioning

confidence: 99%

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges

Meira,

de Castro e Caetano,

Casotti

et al. 2023

Genes

View full text Add to dashboard Cite

Lung cancer is a highly aggressive neoplasm and, despite the development of recent therapies, tumor progression and recurrence following the initial response remains unsolved. Several questions remain unanswered about non-small cell lung cancer (NSCLC): (1) Which patients will actually benefit from therapy? (2) What are the predictive factors of response to MAbs and TKIs? (3) What are the best combination strategies with conventional treatments or new antineoplastic drugs? To answer these questions, an integrative literature review was carried out, searching articles in PUBMED, NCBI-PMC, Google Academic, and others. Here, we will examine the molecular genetics of lung cancer, emphasizing NSCLC, and delineate the primary categories of inhibitors based on their molecular targets, alongside the main treatment alternatives depending on the type of acquired resistance. We highlighted new therapies based on epigenetic information and a single-cell approach as a potential source of new biomarkers. The current and future of NSCLC management hinges upon genotyping correct prognostic markers, as well as on the evolution of precision medicine, which guarantees a tailored drug combination with precise targeting.

show abstract

Integrating frontiers: a holistic, quantum and evolutionary approach to conquering cancer through systems biology and multidisciplinary synergy

Casotti,

Meira,

Zetum

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Cancer therapy is facing increasingly significant challenges, marked by a wide range of techniques and research efforts centered around somatic mutations, precision oncology, and the vast amount of big data. Despite this abundance of information, the quest to cure cancer often seems more elusive, with the “war on cancer” yet to deliver a definitive victory. A particularly pressing issue is the development of tumor treatment resistance, highlighting the urgent need for innovative approaches. Evolutionary, Quantum Biology and System Biology offer a promising framework for advancing experimental cancer research. By integrating theoretical studies, translational methods, and flexible multidisciplinary clinical research, there’s potential to enhance current treatment strategies and improve outcomes for cancer patients. Establishing stronger links between evolutionary, quantum, entropy and chaos principles and oncology could lead to more effective treatments that leverage an understanding of the tumor’s evolutionary dynamics, paving the way for novel methods to control and mitigate cancer. Achieving these objectives necessitates a commitment to multidisciplinary and interprofessional collaboration at the heart of both research and clinical endeavors in oncology. This entails dismantling silos between disciplines, encouraging open communication and data sharing, and integrating diverse viewpoints and expertise from the outset of research projects. Being receptive to new scientific discoveries and responsive to how patients react to treatments is also crucial. Such strategies are key to keeping the field of oncology at the forefront of effective cancer management, ensuring patients receive the most personalized and effective care. Ultimately, this approach aims to push the boundaries of cancer understanding, treating it as a manageable chronic condition, aiming to extend life expectancy and enhance patient quality of life.

show abstract

Targeted cancer therapy: The future of drug combinations

Cited by 3 publications

References 82 publications

Biomarkers in Breast Cancer: An Old Story with a New End

Biomarkers in Breast Cancer: An Old Story with a New End

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges

Integrating frontiers: a holistic, quantum and evolutionary approach to conquering cancer through systems biology and multidisciplinary synergy

Contact Info

Product

Resources

About